Rifaximin: A nonabsorbable, broad-spectrum antibiotic for reduction in the risk for recurrence of overt hepatic encephalopathy

Formulary

Volumn 45, Issue 7, 2010, Pages 210-216

  Feret, Brett ^a   Barner, Benjamin ^b  

^a University of Rhode   (United States)

^b Wal Mart Stores Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISACCHARIDE; ETHINYLESTRADIOL; LACTULOSE; METRONIDAZOLE; MIDAZOLAM; NEOMYCIN; NORGESTIMATE; PROBIOTIC AGENT; RIFAMPICIN; RIFAXIMIN; VANCOMYCIN; ZINC;

ABDOMINAL PAIN; ASCITES; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM INFECTION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG MECHANISM; FATIGUE; HEADACHE; HEPATIC ENCEPHALOPATHY; HUMAN; MUSCLE SPASM; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PERIPHERAL EDEMA; PRURITUS; RECURRENCE RISK; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; TRAVELLER DIARRHEA;

EID: 77958482969     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag. 2009;5:617-626.
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT; and the Members of the Working Party. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the Working Party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-721.
3. Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010;31:537-547.
4. Salix Pharmaceuticals Inc. Xifaxan (rifaximin) tablets, 550 mg NDA 22-554: Briefing document for the Gastrointestinal Drugs Advisory Committee Meeting 23 Feb. 2010. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ GastrointestinalDrugsAdvisoryCommittee/UCM201081.pdf. Accessed June 16, 2010.
5. FDA approves Xifaxan 550 mg tablets for reduction in risk of overt hepatic encephalopathy (HE) recurrence. Available at: http://www.salix.com/news/ stories/20100324.aspx. Accessed June 16, 2010.
6. Huang DB, Dupont HL. Rifaximin a novel antimicrobial for enteric infections. J Infect. 2005;50:97-106.
7. Mas A. Hepatic encephalopathy: from pathophysiology to treatment. Digestion. 2006;73(suppl 1):86-93.
8. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081.
9. Maclayton DO, Eaton-Maxwell A. Rifaximin for treatment of hepatic encephalopathy. Ann Pharmacother. 2009;43:77-84.
10. Hazell A, Butterworth R. Hepatic encephalopathy: an update of pathophysiologic mechanisms. Proc Soc Exp Biol Med. 1999;222:99-112.
11. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy. 2008; 28:1019-1032.
12. Neff G, Kemmer N, Gaddis A, Broda T, Kaiser T. Efficacy of rifaximin in maintenance of remission in patients with hepatic encephalopathy. Am J Gastroenterol. 2009;104(suppl 3):A415
13. Sheikh M, Bass N, Sanyal A, et al. Rifaximin has a favorable longterm safety profile for maintenance of remission from overt hepatic encephalopathy. Am J Gastroenterol. 2009;104(suppl 3):A360.
14. Halsey J. Current and future treatment modalities for Clostridium difcile-associated disease. Am J Health Syst Pharm. 2008;65:705-715.
15. Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother. 2007;41:222-228. (Pubitemid 46340052)
16. Pentikis HS, Connolly M, Trapnell CB, Forbes WP, Bettenhausen DK. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007;27:1361-1369. (Pubitemid 47530442)
17. Xifaxan [package inset]. Morrisville, NJ: Salix Pharmaceuticals,Inc.; March 2010.